Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Adagene Inc (ADAG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ADAG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -35.84% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.86M USD | Price to earnings Ratio - | 1Y Target Price 5.75 |
Price to earnings Ratio - | 1Y Target Price 5.75 | ||
Volume (30-day avg) 34417 | Beta 0.74 | 52 Weeks Range 1.32 - 3.58 | Updated Date 06/19/2025 |
52 Weeks Range 1.32 - 3.58 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -17082.39% |
Management Effectiveness
Return on Assets (TTM) -21.92% | Return on Equity (TTM) -55.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25162669 | Price to Sales(TTM) 890.12 |
Enterprise Value 25162669 | Price to Sales(TTM) 890.12 | ||
Enterprise Value to Revenue 243.81 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 47109600 | Shares Floating 12798488 |
Shares Outstanding 47109600 | Shares Floating 12798488 | ||
Percent Insiders 4.7 | Percent Institutions 34.89 |
Analyst Ratings
Rating 3.33 | Target Price 5.75 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adagene Inc
Company Overview
History and Background
Adagene Inc. is a clinical-stage biotech company founded in 2011. It focuses on discovering and developing antibody-based cancer immunotherapies. It has gone through several financing rounds and strategic partnerships to advance its pipeline.
Core Business Areas
- Antibody Discovery and Development: Adagene's core business revolves around discovering and developing novel antibody-based cancer immunotherapies using its D-timer technology and SAFEbody platform.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates across various cancer types.
- Partnerships and Licensing: Collaborating with pharmaceutical companies to co-develop or license its therapeutic candidates.
Leadership and Structure
Adagene is led by its CEO and has a team of scientists, clinicians, and business professionals. It has a board of directors that provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- ADG106: A fully human agonistic anti-CD137 IgG4 antibody. Currently undergoing clinical trials. Competing with other anti-CD137 antibodies in development by companies like Bristol Myers Squibb.
- ADG126: An anti-CTLA-4 SAFEbody antibody. Currently undergoing clinical trials. Competitors include approved CTLA-4 inhibitors like Yervoy (ipilimumab) from Bristol Myers Squibb and other companies with CTLA-4 inhibitors in clinical trials.
- ADG116: An anti-PD-L1 SAFEbody antibody. Currently undergoing clinical trials. Competitors include marketed PD-L1 inhibitors such as Keytruda (pembrolizumab) from Merck and other companies with PD-L1 inhibitors in clinical trials.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically cancer immunotherapy, is characterized by intense competition, high R&D costs, and rigorous regulatory requirements. High potential reward due to huge patient unmet needs.
Positioning
Adagene is positioned as an innovative player focused on developing differentiated antibody-based therapies using its proprietary technology platforms. It competes with both large pharmaceutical companies and other biotech firms.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars. Adagene targets specific segments within this market, focusing on areas with unmet medical needs and potential for its innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary D-timer technology and SAFEbody platform
- Strong pipeline of antibody-based cancer immunotherapies
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early-stage clinical development of pipeline
- Dependence on successful clinical trial outcomes
- High risk associated with drug development
Opportunities
- Expanding pipeline through internal discovery and collaborations
- Potential for strategic partnerships and licensing agreements
- Advancements in cancer immunotherapy field
- Addressing unmet medical needs in specific cancer types
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Patent disputes
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- PFE
Competitive Landscape
Adagene faces intense competition from established pharmaceutical companies with broader pipelines and greater resources. Adagene's innovative technologies may offer a competitive edge in specific areas.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancement of its pipeline and securing financing.
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization of its drug candidates. Analyst estimates vary widely.
Recent Initiatives: Focus on clinical development of ADG106, ADG126 and ADG116. Also new partnership development for pipeline expansion.
Summary
Adagene is a clinical-stage company with innovative antibody platforms and a promising pipeline. Its financial sustainability relies on clinical success and partnership deals. It faces huge competition but the current unmet patient needs and positive clinical data could allow it to achieve greater success. High risk but potentially high reward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adagene Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-09 | Co- Founder, Chairman, CEO and President of R&D Dr. Peter P. Luo Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 138 | Website https://www.adagene.com |
Full time employees 138 | Website https://www.adagene.com | ||
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.